5-Substituted-2-phenylamino benzamides as MEK inhibitors

Details 5-Substituted-2-phenylamino benzamides as MEK inhibitors 5-Substituted-2-phenylamino benzamides as MEK inhibitors

2005-07-26

2010-06-29

Keys, Rosalynd (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Amino nitrogen containing

C564S253000, C564S167000, C514S619000, C514S228800, C544S063000, C562S454000

Reexamination Certificate

active

07745663

ABSTRACT:
An objective of the present invention is to provide compounds that exhibit strong MEK-inhibiting activity and are stable in vivo and soluble in water, which can be used as preventive or therapeutic agents for proliferative diseases.The compounds of the present invention and pharmaceutically acceptable salts thereof are represented by the following formula (1):[where R1, R2, R3, R4, and X are the same as defined in the present patent application].

REFERENCES:
patent: 2967187 (1961-01-01), Serres, Jr. et al.
patent: 3725417 (1973-04-01), Holland
patent: 4001420 (1977-01-01), Malen et al.
patent: 4469885 (1984-09-01), Mueller et al.
patent: 4501895 (1985-02-01), Mueller et al.
patent: 6440966 (2002-08-01), Barrett et al.
patent: 6750217 (2004-06-01), Barrett et al.
patent: 7001905 (2006-02-01), Biwersi et al.
patent: 2003/0092748 (2003-05-01), Barrett et al.
patent: 2003/0225076 (2003-12-01), Biwersi et al.
patent: 2007/0105859 (2007-05-01), Isshiki et al.
patent: 1 674 452 (2006-06-01), None
patent: 1 780 197 (2007-05-01), None
patent: 48-61448 (1973-08-01), None
patent: 59-210046 (1984-11-01), None
patent: 2003-527379 (2003-09-01), None
patent: WO 99/01426 (1999-01-01), None
patent: WO 00/35436 (2000-06-01), None
patent: WO 01/68619 (2001-09-01), None
patent: WO 02/06213 (2002-01-01), None
patent: WO 03/051877 (2003-06-01), None
patent: WO 2005/028426 (2005-03-01), None
patent: WO 2006/011466 (2006-02-01), None
Patani et al. Chem. Rev. 1996, 96, 3147-3176.
Heintz et al., “Electrosynthesis of aryl-carboxylic acids from chlorobenzene derivatives and carbon dioxide,”Tetrahedron, 44:1631-1636 (1988).
LoRusso et al., “A phase 1 clinical and pharmacokinetic evaluation of the oral MEK inhibitor, CI-1040, administered for 21 consecutive days, repeated every 4 weeks in patients with advanced cancer,”Proc. Am. Soc. Clin. Oncol. 21: 2002 (abstr. 321).
Mitchell et al., “Pharmacokinetics (PK) and pharmacodynamics (PD) of the oral MEK inhibitor, CI-1040, following multiple dose administration to patients with advanced cancer,”Proc. Am. Soc. Clin. Oncol. 21: 2002 (abstr. 320).
Ozaki et al., “Studies on 4(1H)-Quinazolinones. 5. Synthesis and Antiinflammatory Activity of 4(1H)-Quinazolinone Derivatives,”J. Med. Chem., 28:568-576 (1985).
Chardonnens et al., “256. Fluorènacènes et fluorènaphènes. Synthèses dans la série des indèno-fluorènes VIII.1) Méthyl-3-, diméthyl-1,4-, diméthyl-1,3- et triméthy1-1,3,4-cis-fluorènacène,”Helv. Chim. Acta, 41:2436-2440 (1958).
Watson et al., “An Orally Bioavailable Oxime Ether Capsid Binder with Potent Activity against Human Rhinovirus,”J. Med. Chem., 46(15):3181-3184 (2003).
USPTO Restriction Requirement in U.S. Appl. No. 10/572,255, mailed May 29, 2009, 10 pages.
Japanese Patent Office, International Search Report for App. Ser. No. PCT/JP2004/013501, mailed Dec. 28, 2004, 4 pages.
Japanese Patent Office, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/013501, 6 pages.
European Search Report for App. Ser. No. EP 04 77 3160, dated Sep. 4, 2007 (2 pages).
Japanese Patent Office, International Search Report for App. Ser. No. PCT/JP2005/013620, dated Nov. 22, 2005, 3 pages.
Japanese Patent Office, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2005/013620, 6 pages.
Garcia-Echeverria and Sellers, “Drug discovery approaches targeting the PI3K/Akt pathway in cancer,”Oncogene, 27:5511-5526 (2008).
Shioi et al., “Akt/Protein Kinase B Promotes Organ Growth in Transgenic Mice,”Mol. Cell. Biol., 22(8):2799-2809 (2002).
USPTO Non-Final Office Action in U.S. Appl. No. 10/572,255, mailed Sep. 21, 2009, 26 pages.

Affiliated with

Also associated with

Rating

5-Substituted-2-phenylamino benzamides as MEK inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 5-Substituted-2-phenylamino benzamides as MEK inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-Substituted-2-phenylamino benzamides as MEK inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4187620